ROLE OF STATINS IN THE CORRECTION OF ENDOCRINE AND METABOLIC DISORDERS IN POLYCYSTIC OVARY SYNDROME
- Авторлар: CHERNUKHA G.E1, NEMOVA Y.I1, BLINOVA I.V2
-
Мекемелер:
- Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia
- Central Clinical Hospital, Russian Academy of Sciences, Moscow
- Шығарылым: № 5 (2012)
- Беттер: 38-43
- Бөлім: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/246736
- ID: 246736
Дәйексөз келтіру
Аннотация
Objective. To evaluate the combined effects of a drospirenone-containing combination oral contraceptive (COC) versus atorvastatin with COC monotherapy on endocrine and metabolic parameters in patients with polycystic ovary syndrome. Subjects and methods. A prospective study enrolled 42 patients (mean age 23.9 year (range 20.25—27.0 years) with polycystic ovary syndrome, who were randomized into 2 groups: 1) 21 patients who were recommended to have combined therapy with a COC containing 30 μg ethinylestradiol, 3 mg drospirenone and atorvastatin 20 mg/day; 2) 21 patients who received COC monotherapy. Results. The additional use of atorvastatin enhances the antiandrogenic activity of COC, which is characterized by a statistically signif icant reduction in testosterone and and rostenedione levels and free androgen index and by an increase in testosterone-estrogen binding globulin. A combination of atorvastatin and COC has a positive effect on the blood lipid spectrum, which appears as a statistically significant drop in the levels of triglycerides, cholesterol, and low-density lipoproteins and atherogenicity coefficient. Both therapy options exert no negative impact on carbohydrate metabolic parameters, immunoreactive insulin levels, and insulin resistance. The combined therapy shows a 25% fall in the level of high-sensitivity C-reactive protein, one of the predictors of atherosclerosis development, which does not substantially change after COC therapy. Conclusion. The above changes suggest that combined therapy with COV and statins has a number of advantages over COC monotherapy in treating women with polycystic ovary syndrome.
Негізгі сөздер
Толық мәтін
![Рұқсат жабық](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Авторлар туралы
G. CHERNUKHA
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia
Email: c-galina1@yandex.ru
Yu. NEMOVA
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia
Email: j_nemova@hotmail.com
I. BLINOVA
Central Clinical Hospital, Russian Academy of Sciences, Moscow
Email: aiblinovy@mail.ru
Әдебиет тізімі
- Блинова И.В. Функциональное состояние эндотелия и особенности эндокринно-метаболического профиля больных с различными фенотипами синдрома поликистозных яичников: Автореф. дисc.. канд. мед. наук. — М., 2009.
- Шевцова В.Л. Клиническое значение эндокринно-метаболических нарушений при синдроме поликистозных яичников и оптимизация методов их терапии: Автореф. дисc.. канд. мед. наук. — М., 2009.
- Ando H., Takamura T., Ota T. et al. Cerivastatin improves survival of mice with lipopolysaccharide- induced sepsis // J. Pharmacol. Exp. Ther. — 2000. — Vol. 294. — P. 1043—1046.
- Banaszewska B., Pawelczyk L., Spaczynski R.Z. et al. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial // J. Clin. Endocrinol. Metab. — 2007. — Vol. 92. — Р. 456—461.
- Biddinger S.B., Hernandez-Ono A., Rask-Madsen C. et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis // Cell Metab. — 2008. — Vol. 7, № 2. — P. 125 —134.
- Christian R.C., Dumesic D.A., Behrenbeck T. et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome // J. Clin. Endocrinol. Metab. — 2003. — Vol. 88. — Р. 2562—2568.
- Davignon J. Beneficial cardiovascular pleiotropic effects of statins // Circulation. — 2004. — Vol. 109, № 23 (Suppl. 1). — P. III39—III43.
- Diamanti-Kandarakis E., Paterakis T., Alexandraki K. et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin // Hum. Reprod. — 2006. — Vol. 21. — Р. 1426—1431.
- Dobs A.S., Schrott H., Davidson M.H. et al. Effects of highdose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia // Metabolism. — 2000. — Vol. 49. — Р. 1234—1238.
- Duleba A.J., Banaszewska B., Spaczynski R.Z., Pawelczyk L. Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial // Fertil. and Steril. — 2006. — Vol.85. — Р. 996—1001.
- Duleba A.J., Banaszewska B., Spaczynski R.Z., Pawelczyk L. Success of laparoscopic ovarian wedge resection is related to obesity, lipid profile, and insulin levels // Fertil. and Steril. — 2003. — Vol. 79. — Р. 1008—1014.
- Eagleson C.A., Gingrich M.B., Pastor C.L. et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone // J. Clin. Endocrinol. Metab. — 2000. — Vol. 85. — Р. 4047— 4052.
- Guzick D.S. Cardiovascular risk in PCOS // J. Clin. Endocrinol. Metab. — 2004. — Vol. 89. — Р. 3694—3695.
- Izquierdo., Foyouzi N., Kwintkiewicz J., Duleba A.J. Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis // Fertil. and Steril. — 2004. — Vol. 82 (Suppl. 3). — Р. 1193—1197.
- Kassi E., Diamanti-Kandarakis E. The effects of insulin sensitizers on the cardiovascular risk factors in women with polycystic ovary syndrome // J. Endocrinol. Invest. — 2008. — Vol.31, N12. — Р.1124—1131.
- Kazerooni T., Shojaei-Baghini A., Asadi N., Ghaffarpasand F., Kazerooni Y. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, doubleblind, placebo-controlled study // Fertil. and Steril. — 2010. — Vol. 94. — Р. 2208—2213.
- Kelly C.C., Lyall H., Petrie J.R. et al. Low grade chronic inflammation in women with polycystic ovarian syndrome // J. Clin. Endocrinol. Metab. —2001. — Vol. 86. — Р. 2453—2455.
- Lalli C.A., Pauli J.R., Prada P.O. et al. Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet // Metabolism. — 2008. — Vol. 57, № 1. — Р. 57—65.
- Lo J.C., Feigenbaum S.L., Yang J. et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome // J. Clin. Endocrinol. Metab. — 2006. — Vol.91. — Р. 1357—1363.
- McFarlane S.I., Muniyappa R., Francisco R., Sowers J.R. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond // J. Clin. Endocrinol. Metab. — 2002. — Vol. 87. — Р. 1451—1458.
- Raval A., Hunter T., Stuckey B., Hart R.J. Statins for women with polycystic ovary syndrome not actively trying to conceive // Cochrane Database Syst. Rev.-2011. — N10. — CD008565.
- Rizzo M., Corrado E., Coppola G. et al. Markers of inflammation are strong predictors of subclinical and clinical atherosclerosis in women with hypertension // Coron Artery Dis. — 2009. — Vol. 20, № 1. — Р. 15—20.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term healthy risks related to polycystic ovary syndrome // Fertil and Steril. — 2004. — Vol. 81, № 1. — Р. 19—25.
- Rzepczynska I.J., Piotrowski P.C., Wong D.H. et al. Role of isoprenylation in simvastatin-induced inhibition of ovarian theca-interstitial growth in the rat // Biol. Reprod. — 2009. — Vol. 81. — Р. 850—855.
- Talbott E.O., Guzick D.S., Sutton-Tyrrell K. et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women // Arterioscler. Thromb.Vasc. Biol. — 2000. — Vol. 20. — Р. 2414—2421.
- Van Rooijen M., von Schoultz B., Silveira A. et al. Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VI I // Am. J. Obstet. Gynecol. — 2002. — Vol. 186. — Р. 44—48.
- Vryonidou A., Papatheodorou A., Tavridou A. et al. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome // J. Clin. Endocrinol. Metab. — 2005. — Vol. 90. — Р. 2740—2746.
- Wu C.H., Chen Y.F., Wang J.Y. et al. Mutant K-ras oncogene regulates steroidogenesis of normal human adrenocortical cells by the RAF-MEK-MAPK pathway // Br. J.Cancer. — 2002. — Vol. 87. — Р. 1000—1005.
- Wu C.H., Lee S.C., Chiu H.H. et al. Morphologic change and elevation of cortisol secretion in cultured human normal adrenocortical cells caused by mutant p21K-ras protein // DNA Cell Biol. — 2002. — Vol. 21. — Р. 21—29.
Қосымша файлдар
![](/img/style/loading.gif)